Global Therapeutic Vaccines Market - Growth, Trends & Forecasts 2017 - 2022

  • ID: 4388584
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 4
The global therapeutic vaccines market was valued at USD 11 billion in 2015 and is projected to reach USD 51 billion by 2021, at a CAGR of 29% during the forecast period. An increasing prevalence of chronic diseases such as cancer and HIV/AIDS are fueling the market growth.

Market Dynamics

The favorable funding for R&D, increasing investments by companies, and a rise in the prevalence of chronic diseases are some of the factors that are propelling the growth of the market. However, high costs of the vaccines and stringent regulatory guidelines are turning out to be restraints for this market.

Market Segmentation

The global therapeutic vaccines market has been segmented by type and geography.

Type -

Auto Immune Diseases Vaccines

Neurological Disease Vaccines

Cancer Vaccines

Infectious Diseases Vaccines

The cancer vaccines sub-segment contributes the highest share.

Geography -

North America

Europe

Asia-Pacific

Latin America

The Middle East and Africa

North America has the largest market size, followed by Europe. Asia-Pacific is considered to be an emerging market for vaccines due to the rising population and large investments in the field of research and development.

Many players in this market are trying to expand their product portfolio to top the global market. Few companies have adopted product innovation and new product launches as their key business strategies to ensure their dominance in the market.

The major players in the therapeutic vaccines market are:

Key Deliverables:

Market analysis for the global therapeutic vaccines market, with region specific assessments and competition analysis.

Market definition along with the identification of key drivers, restraints, opportunities and challenges.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.

Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.

Identification and analysis of the macro and micro factors that affect the global therapeutic vaccines market.

Insights of the market in the regions that have the highest potential for growth and also to identify the markets that are still untapped
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 General Study Assumptions
1.4 Report Description
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Study timeline
2.4 Study Phases
2.4.1 Secondary Research
2.4.2 Discussion Guide
2.4.3 Market Engineering & Econometric Model
2.4.4 Expert Validation
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry trends
5.1 Current Market Scenario
5.2 Porter's Five Force Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat to New Entrants
5.2.4 Threat to Substitute Products and Services
5.2.5 Competitive Rivalry Within the Industry
6. Market Drivers, Restraints, Opportunities, and Challenges Analysis
6.1 Market Drivers
6.1.1 Favorable Government Funding for Vaccine Development
6.1.2 Increasing Investments by Companies
6.1.3 Rising Prevalence of Disease
6.2 Market Restraints
6.2.1 High Cost of Vaccines
6.2.2 Stringent Regulatory Guidelines
6.3 Market Ppportunities
6.4 Market Challenges
7. Market Segmentation
7.1 By Type
7.1.1 Auto Immune Disease Vaccines
7.1.2 Neurological Disease Vaccines
7.1.2.1 ACC-001
7.1.2.2 CAD 106
7.1.2.3 Parkinson's Vaccine
7.1.2.4 Alzheimer's Vaccine
7.1.3 Cancer Vaccines
7.1.3.1 Multikine
7.1.3.2 PR1 Peptide
7.1.3.3 Trovax
7.1.3.4 CYT004-MelQbG10
7.1.4 Infectious Disease Vaccines
7.1.4.1 Hepatitis C Vaccines
7.1.4.2 HIV/AIDS Vaccine
7.1.4.3 Other Infectious Disease Vaccines
7.2 By Geography
7.2.1 North America
7.2.1.1 USA
7.2.1.2 Canada
7.2.1.3 Mexico
7.2.2 Europe
7.2.2.1 Germany
7.2.2.2 France
7.2.2.3 UK
7.2.2.4 Italy
7.2.2.5 Spain
7.2.2.6 Scandinavia
7.2.2.7 BENELUX
7.2.2.8 Rest of Europe
7.2.3 Asia-Pacific
7.2.3.1 Japan
7.2.3.2 China
7.2.3.3 India
7.2.3.4 South Korea
7.2.3.5 Australia & New Zealand
7.2.3.6 Rest of Asia-Pacific
7.2.4 Middle East & Africa
7.2.4.1 GCC
7.2.4.2 South Africa
7.2.4.3 Rest of Middle East & Africa
7.2.5 South America
7.2.5.1 Brazil
7.2.5.2 Argentina
7.2.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisitions Analysis
8.2 Collaborationa and Partnerships
8.3 New Product Launches
9. Key Vendor Analysis
9.1 Agenus Inc
9.2 Bavarian Nordic
9.3 Celtic Pharma
9.4 Cytos Biotechnology
9.5 Dendreon Corp
9.6 GlaxoSmithKline
9.7 Pfizer
9.8 Merck Serono
9.9 Novartis
9.10 Transgene
10. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll